WELL, GOOD: Trump’s executive order seeks to lower prescription drugs prices, including Medicare patients. If you want to hold prices down, allow compounding pharmacies to continue selling GLP-1 drugs.
Lilly’s First Pill for Diabetes, Weight Loss Shows Positive Study Results WSJ Lilly’s oral GLP-1, orforglipron, demonstrated statistically significant efficacy results and a safety profile consistent with injectable GLP-1 medicines in successful Phase 3 trial Eli Lilly and Company What to Know About Eli Lilly’s Daily Pill for Weight Loss The New York Times How a New Weight-Loss … Read more
Researchers at Mass General Brigham found that by December 2023, over one-third of all new prescriptions for type 2 diabetes were for GLP-1 receptor agonists, such as semaglutide or tirzepatide. New research shows a major shift in how weight loss and type 2 diabetes are managed, with newer drugs like tirzepatide rapidly replacing older medications … Read more
Injectables for type 2 diabetes and weight loss could soon be a thing of the past. Eli Lilly announced Thursday the successful completion of a phase 3 trial of Orforglipron – the first small-molecule GLP-1 that is administered as a once-daily oral pill. The ACHIEVE-1 trial evaluated the efficacy of Orforglipron compared to placebo in … Read more
The experimental drug, orforglipron, led to weight loss of nearly 8 percent at the highest dose, besting Wall Street expectations and sending Lilly’s shares up.
Lilly’s Weight-Loss Pill Data Achieves “Best-Case Scenario”, Sending Rival Novo Shares Into Abyss Eli Lilly shares surged 16% in late afternoon trading—marking their largest intraday gain since August 2023—after the pharmaceutical giant announced earlier that its new weight-loss pill met efficacy goals in a late-stage trial, intensifying—if not turbocharging—its rivalry with Ozempic maker Novo Nordisk. … Read more
2025-04-17T13:01:58Z A sign for Eli Lilly & Co stands outside its corporate headquarters in Indianapolis A significant trial of a daily weight-loss pill has found that it helped people to shed the pounds and reduce their blood sugar levels, making it a contender to join the new wave of drugs that combat obesity and diabetes. … Read more
THURSDAY, April 17, 2025 — Both glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and sodium-glucose cotransporter-2 inhibitors (SGLT2is) are associated with a reduced risk for Alzheimer disease and related dementias (ADRDs) among people with…
What You Should Know: – Eli Lilly and Company announced positive topline Phase 3 results from ACHIEVE-1, a study evaluating the safety and efficacy of orforglipron compared to placebo in adults with type 2 diabetes whose blood sugar was inadequately controlled through diet and exercise alone. – Orforglipron stands out as the first oral small … Read more
